ライフサイエンスコーパス: treatment of @2 with

1 Treatment of blood samples with 0.1% SDS or Triton X-100

2 Treatment of myotubes with 0.5 mmol/L palmitate for 4 h,

3 Treatment of SCs with 40-100 microM glutamate or with 0.

4 promoter was deduced for TrkC-miR2 after the treatment of HCT116 cells with 5-azacytidine, which resu

5 Systemic treatment of rats with 6 mg/kg 6c either simultaneously

6 Treatment of colon explants with 8Br-cGMP also activated

7 The subsequent treatment of (Z)-1 with a minimum amount of THF afforded

8 Combination treatment of 6j with a subcurative dose of miltefosine (

9 More recently, treatment of children with a state-of-the-art self-inact

10 imization of immunosuppression represent the treatment of choice, with a good response rate.

11 In vivo treatment of CKO mice with a CTSS inhibitor abolished th

12 Notably, treatment of Cln1(-/-) mice with a thioesterase (Ppt1)-m

13 Treatment of cystinotic cells with a CMA activator incre

14 Treatment of established infection with a high dose (50

15 Our data suggest that treatment of infected cells with a STAT3 inhibitor and a

16 We investigated the effect of treatment of mice with a cannabinoid receptor 1 (CB1) an

17 Treatment of mice with a history of food-induced anaphyl

18 Treatment of microglia with a metalloproteinase inhibito

19 Treatment of modern silk with a base at different pH and

20 s study is to present a case of endovascular treatment of RAVM with a mixture of NBCA and lipiodol.

21 In addition, treatment of transgenic seedlings with a proteasome inhi

22 Treatment of DC with ACh stimulated the expression of th

23 identified 14 randomized clinical trials for treatment of mNSCLC with active controls submitted to th

24 e rivaroxaban with a P2Y12 inhibitor for the treatment of patients with acute coronary syndromes had

25 linical trials in ARDS and to initiate early treatment of patients with acute lung injury before the

26 Intravenous treatment of mice with adenosine or agonists of ADORA2A

27 The timely recognition and treatment of children with ADHD-type difficulties provid

28 and HDAC inhibition may offer synergy in the treatment of patients with advanced CTCL.

29 kinase inhibitor gefitinib in the first-line treatment of patients with advanced EGFR-mutation-positi

30 nities to develop therapeutic agents for the treatment of disorders with altered energy demand.

31 Treatment of pRBCs with amitriptyline inhibited acid sph

32 thological findings, laboratory results, and treatment of 3 patients with an ultimate diagnosis most

33 enetics, pathophysiology, classification and treatment of angioedema syndromes, with an emphasis on t

34 Treatment of animals with an anti-podoplanin neutralizin

35 Treatment of cells with an Akt activator SC79 or p53 siR

36 Treatment of CKD mice with an IKK inhibitor (IKK 16; 1 m

37 To review the diagnosis, epidemiology, and treatment of HS with an emphasis on advances in the last

38 Similarly, treatment of mice with an IFNAR-neutralizing antibody af

39 Treatment of NitroxylFluor with an HNO donor results in

40 We conclude that treatment of NOD mice with an antibody against CSF-1 rec

41 By contrast, treatment of PCOS mice with an ER stress inhibitor, taur

42 Consistent with this finding, treatment of thymocytes with an antagonist of the inhibi

43 The effect of biannual treatment of children compared with annual treatment of

44 Treatment of mice with anti-PVL antibody also enhanced b

45 ngs may have significant implications in the treatment of RA patients with anti-TNF-alpha drugs and i

46 hould always be judicious, they suggest that treatment of common infections with antibiotics in infan

47 Moreover, treatment of animals with antiinflammatory drugs during

48 Furthermore, treatment of NKT cells with antioxidants led to reduced

49 with other viral infections that showed that treatment of pregnant women with antiviral drugs or hype

50 Treatment of RPE cells with AnxA8 siRNA recapitulated ex

51 Whereas treatment of control HEEs with arachidonic acid increase

52 ing Western blot analysis, we confirmed that treatment of HS rats with artesunate enhanced the phosph

53 Treatment of mice xenografted with ARV-driven CRPC tumor

54 In contrast, treatment of mice with ASO-29 treatment at P15 was minim

55 Treatment of symptomatic mice with ASO7 improved motor f

56 he definitions of airflow limitation and the treatment of people with asthma.

57 Treatment of cells with Bacillus cereus sphingomyelinase

58 However, treatment of patients with benign course may not be need

59 Treatment of TBI patients with beta-blockers offers a po

60 Treatment of these mice with BMS002 from 8 to 20 weeks o

61 l influence on current clinical practice for treatment of patients with bone metastasis from breast c

62 important implications in the management and treatment of patients with breast and ovarian cancer.

63 nhibitor with the potential for prophylactic treatment of hereditary angioedema with C1 inhibitor def

64 imited dilution assays revealed that ex vivo treatment of TNBC cells with C1572 reduced CSC levels by

65 Treatment of 3 with C6 H5 CH2 K and two equivalents of b

66 Our purpose was to evaluate survival after treatment of MPM with cancer-directed surgery and to exp

67 in recent years, opening new horizons in the treatment of patients with cancer.

68 astic leukemia, but fewer results supporting treatment of lymphoma with CAR-19 T cells have been publ

69 ntigen might often be required for effective treatment of MM with CAR-Ts.

70 of patient medical records revealed that the treatment of patients with cardiac glycosides reduced se

71 idating direct HIF-2alpha antagonism for the treatment of patients with ccRCC.

72 nd lead to enhanced clinical outcomes in the treatment of lung disease with cell-based therapies.

73 ta (analysis of guard cell wall epitopes and treatment of tissue with cell wall digesting enzymes, co

74 utinib was approved in the United States for treatment of adult patients with cGVHD after failure of

75 lls and necroptosis in FADD-deficient cells; treatment of both lines with chemotherapeutic drugs elic

76 Treatment of bloodstream parasites with cholesterol-spec

77 Treatment of Lrp1(-/-) OPCs with cholesterol or activati

78 pies represent a significant advance for the treatment of patients with chronic lymphocytic leukemia

79 on the efficacy and safety of oral DAAs for treatment of persons with chronic HCV infection.

80 Treatment of the compounds with chymotrypsin, a digestiv

81 nstrated noninferiority to ertapenem for the treatment of patients with cIAI.

82 f Bcl2, venetoclcax, is highly active in the treatment of patients with CLL.

83 Treatment of NSCLC cells with CMLD-2 produced dose-depen

84 Direct treatment of fibroblasts with conditioned medium collect

85 Treatment of cultured podocytes with connexin 43-specifi

86 Finally, therapeutic treatment of GN mice with connexin 43-specific antisense

87 medicine) so diagnosis, stratification, and treatment of patients with COPD can occur on the basis o

88 precision, effectiveness, and safety of the treatment of patients with COPD.

89 he antiproliferative agent ridaforolimus for treatment of patients with coronary artery disease is un

90 Treatment of mice with CP also leads to differentiation

91 Pre-treatment of HCASMC with Cu((II))ATSM protected against

92 istone has been approved in the U.S. for the treatment of selected patients with Cushing's syndrome.

93 Treatment of HCV(+) MC with DAAs provides a valuable too

94 s with dissociation constants of 115 to 6 pm Treatment of human erythrocytes with DADMe-Immucillin-H

95 Treatment of tubular cells with dasatinib reduced the ex

96 P7 as a promising therapeutic target for the treatment of hematological malignancies with DDR defects

97 Combination treatment of ibrutinib with dexamethasone or vincristine

98 However, the effects of long-term treatment of humans with DHA and EPA on various epigenet

99 insulin infusion can be used to improve the treatment of patients with diabetes.

100 can provide novel therapeutic routes for the treatment of some individuals with diabetes.

101 Treatment of K.2 with dibenzo(18-crown-6) led to the sep

102 ne kinase 2 (ERBB2 or HER2) are the standard treatment of patients with different types of cancer, in

103 Purpose The standard treatment of patients with diffuse large B-cell lymphoma

104 Treatment of cells with dipyridamole, which blocks AICAR

105 Intranasal treatment of mice with DK128 conferred protection agains

106 Treatment of irradiated HSCs with Dkk1 in vitro increase

107 d by combining the prioritized screening and treatment of Egyptian immigrants with domestic preventio

108 r interstitial thermal therapy (LITT) in the treatment of patients with drug-resistant mesial tempora

109 We hypothesized that treatment of AIMSS with duloxetine would improve average

110 n-free survival over gefitinib in first-line treatment of patients with EGFR-mutation-positive NSCLC

111 Foliar treatment of nonmycorrhized plants with either ABA or JA

112 ng interval of beta-lactam agents allows the treatment of strains with elevated MICs that were former

113 Endobronchial coils might have a role in the treatment of patients with emphysema with severe hyperin

114 First, treatment of various phenols with Erlenmeyer-Plochl (Z)-

115 hemoradiation strategies in the nonoperative treatment of patients with esophageal cancer remains unc

116 However, treatment of CD patients with etanercept, a decoy recept

117 Finally, we discovered that treatment of mycobacteria with ethambutol, a front-line

118 eal-time PCR, and ELISA analyses showed that treatment of endothelial cells with EVT conditioned medi

119 Treatment of HT22 cultures with Ex-4 (25 to 100 nM), pri

120 otherapy that is commonly implemented in the treatment of infants with exaggerated physiologic and pa

121 Moreover, treatment of HSCs with exogenous Pot1a inhibits the prod

122 Treatment of mandibular explants with exogenous EDN1 pep

123 Treatment of primary hepatocytes with exogenous LPA blun

124 here is no consensus on the optimal systemic treatment of patients with extranodal marginal zone lymp

125 epresents a potential therapeutic option for treatment of patients with extreme insulin-resistance sy

126 pepsin and amino acid hydrochloride for the treatment of patients with FD and also suggest good to m

127 Here, we show that treatment of CRC cells with fidarestat increases the eff

128 f therapeutics to risk-based, biology-guided treatment of patients with FL.

129 Treatment of HeLa cells with fluorescently labeled PMO c

130 Long-term treatment of Hoxb8 mutants with fluoxetine, a serotonin

131 f the microenvironment, we performed in vivo treatment of xenografted tumors with FPS-ZM1 (1 mg/kg, t

132 Treatment of mice with FTY720, which prevented migration

133 d with periodontal mechanical therapy in the treatment of patients with generalized aggressive period

134 Real-world treatment of AR patients with grass pollen SLIT tablets

135 is the most cost-effective strategy for the treatment of HCV patients with HCC or DCC waitlisted for

136 ere is no currently approved therapy for the treatment of patients with HCM, and to date there have b

137 These findings argue that early treatment of patients with HCU with PEG-CBS may prevent

138 ing HCV replication in cultured cells and in treatment of patients with HCV infection.

139 These findings could improve treatment of patients with HCV infection.

140 Treatment of HCC cells with HDAC inhibitors or knockdown

141 percutaneous solutions are emerging for the treatment of patients with heart failure, it becomes imp

142 lenging problem in the diagnostic workup and treatment of patients with heart failure.

143 e trastuzumab emtansine is indicated for the treatment of patients with HER2-positive metastatic brea

144 hese findings underscore the need to improve treatment of patients with HF.

145 Treatment of bacterial cells with high concentrations of

146 tic cell transplantation (HCT) is a critical treatment of patients with high-risk hematopoietic malig

147 Treatment of mammalian cells with histone deacetylase in

148 Treatment of HAEC with HLA antibody and human complement

149 Treatment of melanoma cells with HSP70 inhibitors decrea

150 to in vivo data obtained from the radiation treatment of mice transplanted with human prostate tumou

151 Treatment of sediments with hydrocarbons resulted in the

152 More importantly, caspofungin treatment of mice with IA resulted in a pattern of incre

153 However, treatment of acute asthma with IB is still uncommon in J

154 Finally, the key to successful treatment of patients with IBS is a good physician-patie

155 Treatment of AGM HSCs with IFN-alpha enhanced long-term

156 f nsp14 G332A virus was diminished following treatment of cells with IFN-beta, and nsp14 G332A genome

157 response, such as USP18 and SOCS1 Transient treatment of PHHs with IFN-lambda4, but not IFN-lambda3,

158 etus when infected at E12, and reciprocally, treatment of pregnant mice with IFN-lambda2 reduced ZIKV

159 Treatment of patients with ileocaecal Crohn's disease wh

160 ese data have important implications for the treatment of melanoma patients with immune checkpoint in

161 Treatment of pancreatoids with (-)-Indolactam-V or phorb

162 Treatment of HOS cells with inhibitors of different endo

163 nzymatic activity changed significantly upon treatment of the cells with inhibitors of human carboxyl

164 of irreversible electroporation (IRE) in the treatment of patients with inoperable hepatocellular car

165 Treatment of donor corneas with interleukin-10 (IL-10) a

166 Treatment of mice with intratracheal instillation of TSG

167 During the first 4 months of treatment of OD with intravitreal ganciclovir, intravitr

168 nfection with live Pseudomonas aeruginosa or treatment of cells with its supernatant.

169 Following treatment of wheat, separately, with jasmonic acid, absc

170 Oral treatment of neonatal lambs with JNJ-53718678, or with a

171 tation has become a routine procedure in the treatment of patients with kidney failure, and requires

172 Consequently, treatment of mice with L. murinus prevented salt-induced

173 -based recommendations for the diagnosis and treatment of patients with LAM are provided.

174 of promising new therapeutic agents for the treatment of diseases with large unmet medical need, par

175 (1:1) patients to receive either an initial treatment of bortezomib with lenalidomide and dexamethas

176 Treatment of mice with lipidated albumin to induce prote

177 We show that treatment of B cells with lipopolysaccharide, the ligand

178 antifibrotic activities and be developed for treatment of patients with liver fibrosis.

179 ed microspheres is increasingly used for the treatment of patients with liver metastases or primary l

180 randomized trial, compared with intensified treatment of midgut NETs with long-acting and repeatable

181 To test the hypothesis that testosterone treatment of older men with low testosterone slows progr

182 The recognition, diagnosis, and treatment of patients with low-flow severe aortic stenos

183 provide a novel therapeutic approach for the treatment of anaemia associated with lower-risk myelodys

184 itled "Nonpharmacologic Versus Pharmacologic Treatment of Adult Patients with Major Depressive Disord

185 prognostic tool to personalize and optimize treatment of patients with MALT lymphoma.

186 esent attractive therapeutic targets for the treatment of patients with medulloblastoma.

187 Notably, intensive intravenous antibiotic treatment of patients with melioidosis resulted in lower

188 Early identification and treatment of children with mental disorders in school se

189 Treatment of severe asthmatics with mepolizumab signific

190 The appropriate treatment of children with mild traumatic brain injury (

191 Weekly treatments of mice with MN-anti-miR-10b and low-dose dox

192 nd etanercept and were well tolerated in the treatment of patients with moderate-to-severe chronic pl

193 PAK1/2/3 and MEK1/2 may be effective in the treatment of patients with MPNSTs.

194 ve antiviral coverage, which facilitates the treatment of patients with multiple infections.

195 t mechanisms of action are available for the treatment of patients with multiple myeloma (MM), includ

196 This one-step procedure involves treatment of anilines with N-chlorosuccinimide (NCS) and

197 are to provide guidelines for diagnosis and treatment of patients with NCP and to summarize current

198 oal in mind, we investigated the effect of a treatment of mice with near infrared (NIR) light on syna

199 known primary tumor is critical for surgical treatment of patients presenting with neuroendocrine tum

200 approved gemtuzumab ozogamicin (GO) for the treatment of adults with newly diagnosed CD33(+) acute m

201 addresses two key clinical questions in the treatment of patients with newly diagnosed primary CNS l

202 te gave mono- and dialkylation products, and treatment of the former with Ni(OAc)2 or Pd(OAc)2 afford

203 d to be effective and well tolerated for the treatment of patients with ocular hypertension and open-

204 Treatment of aryldiynes 1 with one equivalent of iodine

205 Treatment of Zr2 with one equivalent of KCH2 C6 H5 and t

206 Chronic treatment of mice with organophosphate for 180 days conf

207 y of denosumab, which is widely used for the treatment of postmenopausal women with osteoporosis.

208 valuating a CRF1 receptor antagonist for the treatment of PTSD, combined with other negative trials o

209 Treatment of BMDCs with oxLDL ICs increased expression o

210 Treatment of prostate cancer with paclitaxel often fails

211 Dopaminergic medications used in the treatment of patients with Parkinson's disease are assoc

212 ntial of such a stimulation strategy for the treatment of patients with pathological tremor.

213 verview of the presentation, evaluation, and treatment of immunocompetent patients with PCNSL.

214 results of recent phase 3 studies, systemic treatment of advanced disease with peptide receptor radi

215 s a RhoA dependent process and we found that treatment of adherent platelets with PGI2 caused inhibit

216 The treatment of cells with pharmacological inhibitors, such

217 Treatment of cells with phorbol ester or histone deacety

218 Treatment of cancer cells with PI3K inhibitors or taxane

219 : Avelumab showed antitumour activity in the treatment of patients with platinum-refractory metastati

220 Treatment of CIA with PLP-LCL significantly suppressed j

221 eosinophil counts and may have value in the treatment of eosinophilic granulomatosis with polyangiit

222 esonance (MR) cholangiopancreatography-based treatment of patients with possible choledocholithiasis.

223 This leads to uncertainty regarding the treatment of older patients with potentially toxic but a

224 molecular diagnostics should enable targeted treatment of patients with pre-MDR-TB to prevent further

225 Treatment of IBD with PRF results in significant improve

226 Bevacizumab is approved for the treatment of patients with progressive glioblastoma on t

227 them have had a high clinical impact on the treatment of patients with prostate cancer.

228 Treatment of NH-sulfoximines with pseudocyclic benziodox

229 th CFTR modulators may be beneficial for the treatment of CF patients with PTCs.

230 d-type and VacA-deficient H. pylori strains, treatment of cells with purified VacA proteins and infec

231 ontrast, trials that compare single modality treatment of chemotherapy alone with radiotherapy alone

232 1 of the largest patient-level data sets on treatment of DME with ranibizumab.

233 e potential of repurposing amlexanox for the treatment of patients with RDEB harboring PTC mutation i

234 In contrast, treatment of macrophages with recombinant Wnt5a caused a

235 Treatment of P301S neurons with recombinant ApoE (E2, E3

236 inhibitor of PI3Kdelta, is approved for the treatment of patients with relapsed chronic lymphocytic

237 In this model, separate treatment of hyperglycemia with rosiglitazone or hyperte

238 roduction of inflammatory mediators, because treatment of astrocytes with rPrP(c) increased secretion

239 Treatment of CLL patients with RTX is associated with CD

240 e analysis of antibiotics used for empirical treatment of patients with sepsis and septic shock, that

241 sion of antipseudomonal beta-lactams for the treatment of patients with sepsis was associated with si

242 sion of antipseudomonal beta-lactams for the treatment of patients with sepsis was eligible.

243 of the proteasome have been validated in the treatment of multiple myeloma, with several FDA-approved

244 Bariatric surgery for the treatment of adolescents with severe obesity is becoming

245 Treatment of A. fumigatus with Sph3h disrupted A. fumiga

246 porting of RCTs examining chemoradiation for treatment of patients with squamous cell carcinoma of th

247 (DANish Study of Optimal Acute Treatment of Patients With ST-elevation Myocardial Infar

248 3-DEFER (Third DANish Study of Optimal Acute Treatment of Patients With ST-elevation Myocardial Infar

249 Treatment of dyslipidaemia with statins has been challen

250 epilepticus is an emergency; however, prompt treatment of patients with status epilepticus is challen

251 the increase in ChAT activity observed upon treatment of cells with stolonidiol and show that this e

252 is of this cohort, a treatment algorithm for treatment of patients with symptomatic intestinal melano

253 tcomes between parents and caregivers in the treatment of infants with T18 and T13.

254 ive brain tumors.Significance: Combinatorial treatment of glioblastoma with temozolomide and a novel

255 Accordingly, treatment of 1 with the nucleophiles PMe2Ph and Ar-N ide

256 tial objective measurement for diagnosis and treatment of AR combined with the NAC model.

257 Furthermore, treatment of atherosclerotic-MSCs with the reactive oxyg

258 The results showed that treatment of CCPs with the asymptomatic form of the dise

259 HDAC6 inhibition and treatment of cells with the intracellular Ca(2+) chelato

260 Treatment of cells with the non-genotoxic UPR agonist th

261 R and HER2 was investigated before and after treatment of cells with the tyrosine-kinase inhibitor Ge

262 The treatment of control mitochondria with the acetylating a

263 Treatment of cultured PSC with the Jak1/2 inhibitor ruxo

264 Treatment of HDLECs with the pro-inflammatory cytokines

265 Additionally, treatment of HGPS TEBVs with the proposed therapeutic Ev

266 the effectiveness and safety of endovascular treatment of intracranial aneurysms with the use hydroge

267 or the design of antifibrotic agents for the treatment of IPF along with the patent literature from t

268 Treatment of mesenchymal cells with the Cat L inhibitor

269 Results from a phase 2 study for the treatment of MF with the Janus kinase 1/2 (JAK1/2) inhib

270 Treatment of mice with the ADRB3 agonist CL316,243 (CL)

271 ined the effects of microglia depletion, via treatment of mice with the CSF-1 receptor antagonist PLX

272 Treatment of mice with the phosphodiesterase-5 inhibitor

273 Treatment of mice with the YAP inhibitor verteporfin (VP

274 Long-term treatment of mpkCCD14 cells with the type 2 vasopressin

275 tant change to current clinical practice for treatment of MRSA infection, with the potential to signi

276 Treatment of neurons with the calcineurin inhibitors FK5

277 Treatment of Nlrp3A350V mice with the TNF inhibitor etan

278 Treatment of NSCLC explants with the targeted agent TRAI

279 Treatment of PA14 with the FDA-approved anti-inflammator

280 onse to pathogen infection, we observed that treatment of plants with the actin-modifying agent latru

281 Treatment of primary monocytes with the NLRP3 inhibitor

282 Daily treatment of rats with the first-in-class NAMPT stimulat

283 Treatment of STZ-rats with the GHRH agonist, MR-409, pre

284 Transcatheter treatment of TR with the MitraClip system seems to be sa

285 In vivo treatment of tumors with the Hedgehog inhibitor vismodeg

286 idence supports the use of omalizumab in the treatment of patients with therapy-refractory CIndU.

287 hages, with substantial implications for the treatment of cancer with these agents.

288 the effectiveness of angiotensin II for the treatment of patients with this condition.

289 ble safety profile, WTX101 could improve the treatment of patients with this debilitating condition.

290 sary for spatial memory in young mice, while treatment of brain slices with TIMP2 antibody prevents l

291 Topical treatment of mice with TIP39 accelerated wound repair, w

292 Concordantly, treatment of mice with TNP470, a non-canonical Wnt5a inh

293 Treatment of KFs with trichostatin A, which increased th

294 However, treatment of THP(-/-) mice with truncated THP after isch

295 nt in an artificial pancreas for an improved treatment of patients with type 1 diabetes mellitus.

296 The role of incretin-based drugs in the treatment of patients with type 2 diabetes admitted to h

297 This DNAzyme might be developed for treatment of patients with UC.

298 Treatment of cells with various statins strongly increas

299 and safety of WTX101 in the initial or early treatment of patients with Wilson's disease.

300 Treatment of endotoxic mice with YW3-56, a peptidylargin